{"id":"placebo-matched-to-prednisone","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL15720","moleculeType":"Small molecule","molecularWeight":"358.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is not an active pharmaceutical agent but rather an inert control comparator used in randomized controlled trials to evaluate the efficacy of prednisone. Placebo-matched formulations are manufactured to be indistinguishable from the active drug in appearance, taste, and packaging to maintain blinding in clinical studies.","oneSentence":"A placebo formulation designed to match the appearance and administration route of prednisone for use as a control in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:41:57.598Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clinical trial control comparator (not a therapeutic indication)"}]},"trialDetails":[{"nctId":"NCT06934915","phase":"EARLY_PHASE1","title":"Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder","status":"NOT_YET_RECRUITING","sponsor":"Christopher John McDougle, M.D.","startDate":"2026-11","conditions":"Autism Spectrum Disorder, Autism Spectrum Disorders, Autistic Disorder","enrollment":32},{"nctId":"NCT07207954","phase":"PHASE1","title":"Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Lifordi Immunotherapeutics, Inc.","startDate":"2025-10-06","conditions":"Rheumatoid Arthritis","enrollment":176},{"nctId":"NCT02257736","phase":"PHASE3","title":"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2014-11-26","conditions":"Prostatic Neoplasms","enrollment":982},{"nctId":"NCT03748641","phase":"PHASE3","title":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-01-25","conditions":"Castration-Resistant Prostatic Cancer","enrollment":765},{"nctId":"NCT06585774","phase":"PHASE3","title":"A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-01-21","conditions":"Chronic Graft-versus-host-disease","enrollment":240},{"nctId":"NCT05811351","phase":"PHASE2","title":"A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-03-06","conditions":"Geographic Atrophy","enrollment":305},{"nctId":"NCT05379634","phase":"PHASE2","title":"A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-05","conditions":"Myositis","enrollment":36},{"nctId":"NCT05171816","phase":"PHASE3","title":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-24","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":110},{"nctId":"NCT06952803","phase":"PHASE3","title":"A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-08-06","conditions":"Prostate Cancer","enrollment":700},{"nctId":"NCT05039619","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-05-12","conditions":"Lupus Nephritis","enrollment":40},{"nctId":"NCT04206553","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-10-28","conditions":"Bullous Pemphigoid","enrollment":106},{"nctId":"NCT06624670","phase":"PHASE3","title":"A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2025-02-04","conditions":"Pyoderma Gangrenosum","enrollment":90},{"nctId":"NCT03274492","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-11-16","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1000},{"nctId":"NCT04221477","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-08-10","conditions":"Lupus Nephritis","enrollment":271},{"nctId":"NCT07060638","phase":"PHASE2","title":"Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial","status":"RECRUITING","sponsor":"Samer Gawrieh","startDate":"2026-01-27","conditions":"Alcohol-associated Hepatitis","enrollment":216},{"nctId":"NCT03732820","phase":"PHASE3","title":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-10-31","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":895},{"nctId":"NCT04493853","phase":"PHASE3","title":"Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-07-13","conditions":"Hormone-Sensitive Prostate Cancer","enrollment":1012},{"nctId":"NCT07168161","phase":"PHASE3","title":"BDB-001 Phase III Trial in ANCA-Associated Vasculitis","status":"RECRUITING","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2025-11-10","conditions":"ANCA Associated Vasculitis (AAV)","enrollment":300},{"nctId":"NCT03584516","phase":"PHASE2, PHASE3","title":"GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2019-01-17","conditions":"Chronic Graft-versus-host Disease","enrollment":155},{"nctId":"NCT06143891","phase":"PHASE3","title":"A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-01-23","conditions":"Chronic Graft Versus Host Disease","enrollment":260},{"nctId":"NCT04824092","phase":"PHASE3","title":"Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2021-05-11","conditions":"Diffuse Large B-cell Lymphoma","enrollment":899},{"nctId":"NCT03139604","phase":"PHASE3","title":"GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-07-19","conditions":"Graft-versus-host Disease (GVHD)","enrollment":439},{"nctId":"NCT04354649","phase":"PHASE2","title":"Immune-Mediated Pathophysiology And Clinical Triage Program","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2021-09-16","conditions":"Arthritis, Arthralgia","enrollment":46},{"nctId":"NCT03072238","phase":"PHASE3","title":"Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-06-30","conditions":"Metastatic Prostate Cancer","enrollment":1101},{"nctId":"NCT01974440","phase":"PHASE3","title":"A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-01-31","conditions":"Lymphoma","enrollment":403},{"nctId":"NCT02994927","phase":"PHASE3","title":"A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-03-15","conditions":"ANCA-Associated Vasculitis","enrollment":331},{"nctId":"NCT02043678","phase":"PHASE3","title":"Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-30","conditions":"Prostatic Neoplasms","enrollment":806},{"nctId":"NCT04072822","phase":"PHASE2","title":"Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis","status":"COMPLETED","sponsor":"Indiana University","startDate":"2020-07-10","conditions":"Alcoholic Hepatitis","enrollment":147},{"nctId":"NCT01855750","phase":"PHASE3","title":"A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-09-03","conditions":"Lymphoma","enrollment":838},{"nctId":"NCT01715285","phase":"PHASE3","title":"A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-02-12","conditions":"Prostate Neoplasms","enrollment":1209},{"nctId":"NCT05542355","phase":"PHASE1","title":"EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease","status":"TERMINATED","sponsor":"Exeliom Biosciences","startDate":"2023-03-20","conditions":"Crohn Disease","enrollment":8},{"nctId":"NCT06631300","phase":"PHASE1, PHASE2","title":"A Randomized, Placebo-controlled Trial of Prednisone in Refractory Restless Legs Syndrome: a Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"Scripps Health","startDate":"2024-10-01","conditions":"Restless Legs Syndrome","enrollment":50},{"nctId":"NCT02550652","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-11-13","conditions":"Lupus Nephritis","enrollment":126},{"nctId":"NCT03861390","phase":"PHASE1, PHASE2","title":"Woodsmoke Particulate + Prednisone","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2019-03-22","conditions":"Airway Inflammation","enrollment":12},{"nctId":"NCT04809623","phase":"PHASE1","title":"Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2021-09-01","conditions":"Cutaneous Lupus Erythematosus","enrollment":3},{"nctId":"NCT04654988","phase":"PHASE4","title":"Study to Evaluate the Efficacy of Immunosuppression in Myocarditis or Inflammatory Cardiomyopathy.","status":"RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2022-12-01","conditions":"Myocarditis, Heart Failure, Endomyocardial Biopsy","enrollment":100},{"nctId":"NCT01972217","phase":"PHASE2","title":"Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-04-01","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":158},{"nctId":"NCT05003713","phase":"PHASE1","title":"Single and Multiple Ascending Dose Study of CORT125236 in Healthy Participants","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2021-08-03","conditions":"Healthy","enrollment":82},{"nctId":"NCT01332097","phase":"PHASE2","title":"Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an Exacerbation","status":"COMPLETED","sponsor":"Mereo BioPharma","startDate":"2011-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":183},{"nctId":"NCT04652414","phase":"PHASE2","title":"Corticosteroids in Community Acquired Pneumonia","status":"WITHDRAWN","sponsor":"Vanderbilt University Medical Center","startDate":"2020-12-01","conditions":"Community-acquired Pneumonia, Cognition Disorder","enrollment":""},{"nctId":"NCT03470311","phase":"PHASE3","title":"Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies","status":"COMPLETED","sponsor":"McMaster University","startDate":"2018-04-26","conditions":"Severe Prednisone Dependent Eosinophilic Asthma","enrollment":20},{"nctId":"NCT03782532","phase":"PHASE3","title":"Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-01-25","conditions":"Asthma","enrollment":486},{"nctId":"NCT02495077","phase":"PHASE2","title":"Effects of Inhibiting Early Inflammation in Kidney Transplant Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-11-02","conditions":"Kidney Transplant","enrollment":290},{"nctId":"NCT03600818","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica","status":"TERMINATED","sponsor":"Sanofi","startDate":"2018-10-09","conditions":"Polymyalgia Rheumatica","enrollment":118},{"nctId":"NCT05303272","phase":"PHASE4","title":"A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV)","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2021-02-01","conditions":"Pemphigus Vulgaris","enrollment":60},{"nctId":"NCT03600805","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA","status":"TERMINATED","sponsor":"Sanofi","startDate":"2018-11-20","conditions":"Giant Cell Arteritis","enrollment":83},{"nctId":"NCT01085097","phase":"PHASE2","title":"A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-09-01","conditions":"Lupus Nephritis","enrollment":46},{"nctId":"NCT04672512","phase":"PHASE1","title":"Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2020-10-23","conditions":"Healthy","enrollment":115},{"nctId":"NCT04249323","phase":"PHASE1","title":"Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2020-01-27","conditions":"Healthy Adults","enrollment":110},{"nctId":"NCT03207815","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2017-07-26","conditions":"Noninfectious Uveitis","enrollment":74},{"nctId":"NCT00562497","phase":"PHASE3","title":"Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)","status":"COMPLETED","sponsor":"Mesoblast, Inc.","startDate":"2008-01-31","conditions":"Graft Versus Host Disease","enrollment":192},{"nctId":"NCT02277223","phase":"PHASE3","title":"Curcumin in Pediatric Ulcerative Colitis","status":"WITHDRAWN","sponsor":"Schneider Children's Medical Center, Israel","startDate":"2020-03-01","conditions":"Ulcerative Colitis","enrollment":""},{"nctId":"NCT01364389","phase":"PHASE2","title":"A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-02-14","conditions":"Polymyalgia Rheumatica, Inflammatory Diseases","enrollment":16},{"nctId":"NCT01714817","phase":"PHASE3","title":"Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2013-01-22","conditions":"Lupus Nephritis","enrollment":695},{"nctId":"NCT03610685","phase":"PHASE4","title":"Inflammation Following Mepolizumab and Oral Corticosteroids in Asthma","status":"COMPLETED","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2018-10-19","conditions":"Asthma","enrollment":33},{"nctId":"NCT01753401","phase":"PHASE4","title":"Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2013-01","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":38},{"nctId":"NCT02836496","phase":"PHASE3","title":"Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-03-07","conditions":"Hypereosinophilic Syndrome","enrollment":108},{"nctId":"NCT00463385","phase":"PHASE2","title":"A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia","status":"COMPLETED","sponsor":"Celgene","startDate":"2007-04-01","conditions":"Myelofibrosis With Myeloid Metaplasia, Myeloid Metaplasia, Myelofibrosis","enrollment":88},{"nctId":"NCT02573012","phase":"PHASE4","title":"Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-03-29","conditions":"Rheumatoid Arthritis","enrollment":314},{"nctId":"NCT03508635","phase":"PHASE1","title":"CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2014-09","conditions":"Healthy","enrollment":130},{"nctId":"NCT02531633","phase":"PHASE3","title":"Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2015-10-16","conditions":"Giant Cell Arteritis","enrollment":161},{"nctId":"NCT00828061","phase":"PHASE1","title":"A Study of the Effects of Single Dose Corticosteroids on Response to Allergens","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-02-04","conditions":"Allergic Rhinitis","enrollment":19},{"nctId":"NCT01656187","phase":"PHASE4","title":"Attenuation of Corticosteroid Induced Hippocampal Changes","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2012-01","conditions":"Organic Memory Impairment","enrollment":46},{"nctId":"NCT00146640","phase":"PHASE3","title":"Prednisone Timed-Release Tablet (TRT) Study: Modified-Release (MR) Formulation of Prednisone Compared to Standard Immediate-Release (IR) Prednisone in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-08-31","conditions":"Rheumatoid Arthritis","enrollment":288},{"nctId":"NCT01522443","phase":"PHASE3","title":"Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer","status":"TERMINATED","sponsor":"Exelixis","startDate":"2012-03","conditions":"Prostate Cancer, Castration Resistant Prostate Cancer, Pain","enrollment":119},{"nctId":"NCT01666314","phase":"PHASE1, PHASE2","title":"Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2012-08-20","conditions":"Prostate Cancer","enrollment":137},{"nctId":"NCT01605227","phase":"PHASE3","title":"Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100","status":"COMPLETED","sponsor":"Exelixis","startDate":"2012-07","conditions":"Prostate Cancer, Castration Resistant Prostate Cancer, Pain","enrollment":1028},{"nctId":"NCT02899026","phase":"PHASE3","title":"Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2018-03-15","conditions":"Polymyalgia Rheumatica","enrollment":""},{"nctId":"NCT00562159","phase":"PHASE3","title":"Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)","status":"COMPLETED","sponsor":"ALK-Abelló A/S","startDate":"2007-11","conditions":"Rhinoconjunctivitis, Rhinitis, Conjunctivitis","enrollment":439},{"nctId":"NCT00550550","phase":"PHASE3","title":"Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)","status":"COMPLETED","sponsor":"ALK-Abelló A/S","startDate":"2007-11","conditions":"Rhinoconjunctivitis, Rhinitis, Conjunctivitis","enrollment":345},{"nctId":"NCT01193049","phase":"PHASE1","title":"A Study on the Effects of a Single Dose of Prednisone on Biomarkers of Allergen Responses in Asthmatics (MK-0000-175)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-08","conditions":"Asthma","enrollment":11},{"nctId":"NCT01210677","phase":"PHASE4","title":"Cardiac Sarcoidosis Response To Steroids Trial","status":"WITHDRAWN","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2014-04","conditions":"Cardiac Sarcoidosis, Sarcoidosis","enrollment":""},{"nctId":"NCT00537381","phase":"PHASE2","title":"An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2007-05","conditions":"Prostatic Neoplasms","enrollment":131},{"nctId":"NCT00889863","phase":"PHASE3","title":"Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-07","conditions":"Systemic Juvenile Idiopathic Arthritis With Active Flare","enrollment":177}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":52,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo matched to prednisone","genericName":"Placebo matched to prednisone","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo formulation designed to match the appearance and administration route of prednisone for use as a control in clinical trials. Used for Clinical trial control comparator (not a therapeutic indication).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}